Your session is about to expire
← Back to Search
Tirzepatide for Obesity
Study Summary
This trial will evaluate the safety and effectiveness of a drug for adolescents with obesity and related conditions. It will last 90 weeks with up to 25 visits.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 210 Patients • NCT05024032Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
For which demographic is this clinical trial ideally suited?
"This research project is accepting up to 150 adolescent candidates with obesity between 12 and 17 years of age."
Are geriatric participants eligible to partake in this trial?
"This trial is only open to adolescent participants aged between 12 and 17, in adherence with the specified inclusion criteria."
To what extent does Tirzepatide pose a hazard to individuals?
"Tirzepatide is considered to be a relatively safe drug, garnering a score of 3 on our team's safety scale. This assessment is largely based on the pre-existing Phase 3 clinical data which demonstrate both its efficacy and low risk profile."
Are there any remaining slots for participants in this experiment?
"Data from clinicaltrials.gov points to this trial no longer recruiting participants, though it was initially posted on October 15th 2023 and updated as recently as October 4th 2023. Fortunately, there are over a thousand other studies that currently have open enrolment for patients looking to participate in medical trials."
How many sites are responsible for overseeing this trial?
"This trial is being administered at 36 different medical sites, such as CenExel iResearch in Decatur, Cotton O'Neil Clinical Research Center in Topeka and Pennington Biomedical Research Centre in Baton Rouge."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger